» Articles » PMID: 22016379

Fatigue in Bronchiectasis

Overview
Journal QJM
Specialty General Medicine
Date 2011 Oct 22
PMID 22016379
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Fatigue is a complex, disabling symptom in non-CF bronchiectasis (nCF-Br). Fatigue can be formally measured using the validated fatigue impact scale (FIS). The relationship between fatigue and clinically important factors such as airflow obstruction, breathlessness or Pseudomonas aeruginosa infection in nCF-Br is unclear.

Aim: To measure the correlation between FIS scores and markers of disease severity in nCF-Br.

Design: A prospective cohort study.

Methods: Patients attending a specialist service were studied. Lung function (FEV(1)% predicted), Medical Research Council dyspnoea score (MRCD), sputum culture results and FIS were recorded. Patients were categorized according to sputum culture into three subgroups: Pseudomonas 'colonization', 'isolation' and neither.

Results: One hundred and seventeen consecutive patients were included. Average FEV(1)% predicted was 64% (SD ±28%). Twelve (10%) patients had Pseudomonas aeruginosa isolation; 47 (40%) patients had P. aeruginosa colonization. Fatigue levels were similar in patients with and without colonization (median 38 versus 32, P = 0.155). Significant fatigue (FIS > 40) was similar in all three Pseudomonas subgroups (P = 0.31, chi-square). Fatigue correlated with MRCD score (r = 0.57, P < 0.001) and FEV(1)% predicted (r = -0.30, P = 0.001). FEV(1)% predicted was lower in patients who had ever isolated or been colonized with P. aeruginosa (P ≤ 0.001).

Conclusion: There are significant correlations between FIS score and MRCD score and FEV(1)% predicted in bronchiectasis. Pseudomonas aeruginosa infection appears to be associated with poorer lung function, and higher MRCD scores, yet there is no significant association between P. aeruginosa status and fatigue.

Citing Articles

Cough in non-cystic fibrosis bronchiectasis.

Kantar A, Song W, Bush A, Chatziparasidis G ERJ Open Res. 2024; 10(6).

PMID: 39624376 PMC: 11610066. DOI: 10.1183/23120541.00330-2024.


Clinical Impacts of Isolation in Patients with Bronchiectasis: Findings from KMBARC Registry.

Song J, Sin S, Kang H, Oh Y, Jeong I J Clin Med. 2024; 13(17).

PMID: 39274224 PMC: 11396479. DOI: 10.3390/jcm13175011.


Dual bronchodilators in Bronchiectasis study (DIBS): protocol for a pragmatic, multicentre, placebo-controlled, three-arm, double-blinded, randomised controlled trial studying bronchodilators in preventing exacerbations of bronchiectasis.

Morton M, Wilson N, Homer T, Simms L, Steel A, Maier R BMJ Open. 2023; 13(8):e071906.

PMID: 37562935 PMC: 10423789. DOI: 10.1136/bmjopen-2023-071906.


Effects of Pulmonary Rehabilitation on Systemic Inflammation and Exercise Capacity in Bronchiectasis: A Randomized Controlled Trial.

Araujo A, Figueiredo M, Lomonaco I, Lundgren F, Mesquita R, Pereira E Lung. 2022; 200(3):409-417.

PMID: 35543710 DOI: 10.1007/s00408-022-00540-3.


Dissecting the fatigue experience: A scoping review of fatigue definitions, dimensions, and measures in non-oncologic medical conditions.

Billones R, Liwang J, Butler K, Graves L, Saligan L Brain Behav Immun Health. 2021; 15:100266.

PMID: 34589772 PMC: 8474156. DOI: 10.1016/j.bbih.2021.100266.